A retrospective chart review compared the difference in outcomes between Black patients and White patients with advanced RCC for 3 first-line therapies.

The diagnosis, staging, and management of renal cell carcinoma (RCC ... 19% of patients have locally advanced disease, and 20% of patients have metastatic disease. Surgical resection is the ...

Your healthcare provider will also look for evidence of spread to nearby tissues or distant regions of the body. Kidney cancer is somewhat unique. This is because surgery may be done even with ...

The results of this first phase 2 study of belzutifan combined with cabozantinib suggest that dual targeting of HIF-2α and VEGF pathways might be an effective first-line treatment strategy in advanced ...

In patients with advanced clear cell renal cell carcinoma (ccRCC), sitravatinib (tyrosine kinase inhibitor) has shown efficacy both alone and in combination with nivolumab (anti-PD-1). Here ...

More information: Tejas Jammihal et al, Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma, Nature Cancer (2024). 10.1038/s43018-024-00896-w ...

Metastatic clear cell renal cell carcinoma (mccRCC), an aggressive type of kidney cancer, has historically presented limited treatment options. Immune checkpoint inhibitors, a form of immunotherapy, ...

As a single agent in the treatment of advanced RCC, at the dose and schedule ... ovarian, and lung cancer. [25] Previous studies have also reported frequent fatigue, diarrhea, and nausea.

If you aren’t healthy enough to withstand surgery, alternative, localized treatments may be recommended for you to consider instead. These include: Kidney cancer that has advanced to stage 4 requires ...

In patients with advanced clear cell renal cell carcinoma (ccRCC), sitravatinib (tyrosine kinase inhibitor) has shown efficacy both alone and in combination with nivolumab (anti-PD-1). Here ...